AstraZeneca Stock

AstraZeneca Current Assets

The Current Assets of AstraZeneca (AZN.L) as of Aug 22, 2026 is 28.72 B USD. In the previous year, Current Assets was 25.83 B USD — a change of 11.21% (higher).

Current Assets

28.72 BUSD

YoY

11.21%

Last updated:

Current Assets of AstraZeneca is 2026 28.72 B USD. Current Assets of AstraZeneca was 2025 25.83 B USD. It decreases by 11.21% higher compared to the previous year.

The AstraZeneca Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
15.59 B USD
Jan 1, 2019
15.56 B USD
Jan 1, 2020
19.54 B USD
Jan 1, 2021
26.24 B USD
Jan 1, 2022
22.59 B USD
Jan 1, 2023
25.05 B USD
Jan 1, 2024
25.83 B USD
Jan 1, 2025
28.72 B USD
The AstraZeneca Current Assets history
YEARCurrent AssetsYoY
28.72 BUSD+11.21%
25.83 BUSD+3.09%
25.05 BUSD+10.89%
22.59 BUSD-13.91%
26.24 BUSD+34.28%
19.54 BUSD+25.58%
15.56 BUSD-0.18%
15.59 BUSD+18.56%
13.15 BUSD-0.84%
13.26 BUSD-17.15%
16.01 BUSD-4.13%
16.70 BUSD-17.89%
20.34 BUSD+6.76%
19.05 BUSD-18.97%
23.51 BUSD-6.47%
25.13 BUSD+5.77%
23.76 BUSD+49.73%
15.87 BUSD-6.63%
17.00 BUSD+0.35%
16.94 BUSD+22.99%
13.77 BUSD+5.72%
13.03 BUSD+12.35%
11.59 BUSD-4.40%
12.13 BUSD+17.00%
10.36 BUSD-1.44%
10.52 BUSD+6.06%
9.91 BUSD+122.92%
4.45 BUSD-5.45%
4.70 BUSD-9.47%
5.20 BUSD+6.49%
4.88 BUSD+7.11%
4.56 BUSD-6.76%
4.89 BUSD+30.05%
3.76 BUSD
Access this data via the Eulerpool API

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

Current Assets of AstraZeneca is 28.72 B USD in 2026.

Current Assets of AstraZeneca changed from 25.83 B USD to 28.72 B USD, representing a 11.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's AstraZeneca historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — AstraZeneca

All Key Metrics — AstraZeneca